Oxford Asset Management’s Kyntra Bio KYNB Stock Holding History

Oxford Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,296	Closed	-$1.39M	–	594
2019 Q4	$1.39M	Buy	1,296 +631	+95%	+$644K	0.04%	637
2019 Q3	$614K	Buy	+665	New	+$730K	0.01%	1176
2019 Q2	–	Sell	-1,160	Closed	-$1.58M	–	1791
2019 Q1	$1.58M	Buy	+1,160	New	+$1.57M	0.03%	703
2017 Q2	–	Sell	-4,510	Closed	-$2.78M	–	1541
2017 Q1	$2.78M	Sell	4,510 -1,227	-21%	-$747K	0.07%	313
2016 Q4	$3.07M	Buy	5,737 +1,491	+35%	+$744K	0.11%	192
2016 Q3	$2.2M	Sell	4,246 -2,593	-38%	-$1.22M	0.07%	387
2016 Q2	$2.81M	Buy	6,839 +2,233	+48%	+$1.02M	0.09%	296
2016 Q1	$2.45M	Sell	4,606 -255	-5%	-$127K	0.07%	324
2015 Q4	$3.77M	Buy	+4,861	New	+$3.23M	0.09%	247

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Oxford Asset Management's KYNB Position: Q1 2020 in Review

Oxford Asset Management sold out of Kyntra Bio (KYNB) in Q1 2020, closing a stake of 1,296 shares — an estimated $1.39M sold.

Oxford Asset Management first reported a position in KYNB in Q4 2015 and held it in 9 quarters. The position peaked at $3.77M in Q4 2015. 187 funds tracked by Wall St. Rank hold KYNB as of Q1 2020.

Oxford Asset Management reported no remaining Kyntra Bio position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 1,296 Kyntra Bio shares in Q1 2020, an estimated $1.39M.
Oxford Asset Management first reported a position in Kyntra Bio in Q4 2015 and held it in 9 quarters.
Oxford Asset Management's Kyntra Bio position peaked at $3.77M in Q4 2015.
187 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.